Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Crinetics Pharmaceuticals (CRNX) Stock Price & Analysis
416 Followers
CRNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.76 - $49.58
Previous Close$44.22
Volume563.21K
Average Volume (3M)807.33K
Market Cap
$3.45B
Enterprise Value$2.94B
Total Cash (Recent Filing)$554.65M
Total Debt (Recent Filing)$52.17M
Price to Earnings (P/E)-12.0
Beta0.51
Next Earnings
May 10, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.70
Shares Outstanding69,596,202
10 Day Avg. Volume596,484
30 Day Avg. Volume807,330
Standard Deviation0.16
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.59
Price to Sales (P/S)4151.23
Price to Cash Flow (P/CF)-19.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-196.24K
Enterprise Value/Gross Profit621.40
Enterprise Value/Ebitda-14.48
Forecast
1Y Price Target
$58.92Price Target Upside39.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Crinetics Pharmaceuticals News
PremiumCompany Announcements
Crinetics Pharmaceuticals Launches New Deferred Compensation Plan
Ownership Overview
9.71% Insiders
25.61% Mutual Funds
12.86% Other Institutional Investors
51.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $15.76 and its highest was $49.58 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Currently, no data Available
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is May 10, 2024 which is in 13 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Feb 28, 2024. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.863 by -$0.037.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -$0.81.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 77,929,535 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.863. Following the earnings report the stock price went down -4.256%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 179M.
---
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.92 (39.89% Upside)
$58.92 (39.89% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 47.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.73%
12-Months-Change
Fundamentals
Return on Equity
-50.16%
Trailing 12-Months
Asset Growth
80.41%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
CRNX Earnings Call
Q4 2024
0:00 / 0:00
---
CRNX Stock 12 Months Forecast
Average Price Target
$58.92
▲(39.89% Upside)
Technical Analysis
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+53.21%
assigned a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +53.21% per trade.
---